01 Loehr influenza 508

Document text

National Center for Immunization & Respiratory Diseases
Influenza Work Group— Introduction
Dr. Jamie Loehr (Work Group Chair)
Advisory Committee on Immunization Practices
April 15, 2025
Influenza Work Group
ACIP Members
•Jamie Loehr (Chair)
•Robert Schechter
•Albert Shaw
•Keipp Talbot
Ex Officio
•Timothy Brennan (FDA)
•Uzo Chukwuma (IHS)
•Walter Greenhalgh (HRSA)
•Michael Ison (NIH)
•Cynthia Nolletti (FDA)
•Jo Resnick (FDA)
•Chris Roberts (NIH)Liaison Representatives and 
Consultants
•Robert Atmar
•Kevin Ault
•Ed Belongia
•Hank Bernstein
•Kris Bryant
•Sarah Coles
•Sandra Fryhofer
•Robert Hopkins
•Wendy Keitel
•Camille Kotton
•Krissy Moehling•Zackary Moore
•Flor Munoz
•Caitlin Newhouse
•Jesse Papenburg
•William Schaffner
•Ken Schmader 
•Tamara Sheffield
•Angela Sinilaite
•Peter Szilagyi
•Matthew Zahn
CDC Lead
•Lisa Grohskopf
2
CDC Participants
•Lenee Blanton
•Karen Broder
•Alicia Budd
•Kayla Calhoun
•Jessie Chung
•Jennifer DeCuir
•Sascha Ellington
•Tarayn Fairlie
•Jill Ferdinands
•Brendan Flannery
•Andrew Kroger
•Samantha Olson
•David Shay
•Tom Shimabukuro
•Naomi Tepper
3
Influenza Vaccine Composition for 2025 -26
• On March 15, 2025, the U. S. Food and Drug Administration made recommendations for the 
composition of U.S. -licensed influenza vaccines for the 2025- 26 influenza season.
• The 2025- 26 vaccine composition includes an update to the influenza A(H3N2 ) component.
-For egg -based vaccines:
›an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
›an A/Croatia/10136RV/2023 (H3N2) -like virus; and
›a B/Austria/1359417/2021 (B/Victoria lineage) -like virus
-For cell culture and recombinant vaccines:
›an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
›an A/District of Columbia/27/2023 (H3N2) -like virus; and
›a B/Austria/1359417/2021 (B/Victoria lineage) -like virus
4https://www.fda.gov/vaccines -blood -biologics/influenza -vaccine -composition -2025 -2026 -us-influenza- season
Influenza Vaccine Effectiveness (VE) Estimates
Updates:
• Interim Estimates of 2024 –25 Seasonal Influenza Vaccine Effectiveness
⁻Dr. Aaron Frutos (CDC/NCIRD/ID)
• Interim Influenza Vaccine Effectiveness Against Laboratory -Confirmed Influenza , California , 
October 2024— January 2025
⁻Dr. Sophie Zhu (California Department of Public Health and CDC/PHIC) and Dr. Joshua Quint  
(California Department of Public Health)Issue:
• Influenza vaccine effectiveness varies and is assessed annually through several CDC platforms 
focusing on laboratory- confirmed influenza outpatient visits and hospitalizations in adult and 
pediatric populations.
• VE estimates are presented to the ACIP as they become available.
• Preliminary 2024 -25  VE estimates are available from CDC platforms and from the California 
Department of Public Health.
5
FluMist (LAIV3) Self -/Caregiver Administration 
Updates:
•FluMist Self/Caregiver Administration 
⁻Dr. Allyn Bandell, AstraZenecaIssue:
•On September 20, 2024, FDA approved FluMist for self or caregiver administration.
•This program is expected to be available for the 2025 -26 influenza season.
6
Upcoming Votes
7•Vote concerning updates to the 2025-26 ACIP influenza statement is 
expected at the June 2025 ACIP meeting.
For more information, contact CDC
1-800- CDC- INFO (232- 4636)
TTY:  1 -888- 232- 6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.